Tolcapone and fulminant hepatitis

Lancet

Volumn 352, Issue 9132, 1998, Pages 958-

  Assal, Frédéric ^a   Spahr, Laurent ^b   Hadengue, Antoine ^b   Rubbici Brandt, Laura ^a   Burkhard, Pierre R ^b  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LEVODOPA; LIVER ENZYME; TOLCAPONE;

AGED; ARTICLE; CASE REPORT; FEMALE; HEPATITIS; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0032547507     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)61511-5     Document Type: Article

References (4)

1. 1 Oertel WH, Eichhorn TE, Pogarell O. COMT inhibition: anm overview of clinical data with tolcapone in fluctuating and non fluctuating patients with Parkinson's disease. Clin Neuropharmacol 1998; 21: 17-25.
2. 2 Waters CH, Kurth M, BAiley P, et al, and the Tolcapone Stable Study Group. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology 1997; 49: 665-71.
3. 3 Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neursosurg Psychiatry 1997; 63: 421-28.
4. 4 Rajput AH, Martain W, Saint-Hilaire M-H, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. NEurology 1997; 49: 1066-71.